Synapse Pharmatech Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Synapse Pharmatech Pharmaceutical Export Portfolio Dataset — 2 Products, $510.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Synapse Pharmatech — Pharmaceutical Exporter Profile (2026) | 2 Products, $510.6K Trade | TransData Nexus

Synapse Pharmatech

Indian Pharmaceutical Exporter · Respiratory Specialist · $510.6K Total Trade · DGFT Verified

Synapse Pharmatech is an Indian pharmaceutical exporter with a total trade value of $510.6K across 2 products in 2 therapeutic categories. Based on 11 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Tiotropium ($350.0K), Protein ($160.6K), .

Synapse Pharmatech — Export Portfolio & Destination Treemap

Synapse Pharmatech pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Synapse Pharmatech? — Company Overview & Market Position

Synapse Pharmatech, established in 2009, is an India-based pharmaceutical company specializing in the manufacture and export of finished pharmaceutical formulations. The company is headquartered in Ahmedabad, Gujarat, India, with additional facilities in North India and South India. Synapse Pharmatech operates as a privately held entity, with its ownership structure not publicly disclosed. The company's Corporate Identification Number (CIN) is not available in the provided sources. While specific revenue figures are not publicly disclosed, Synapse Pharmatech has reported a total export value of $511,000 USD from 11 shipments between 2022 and 2026. The company offers a diverse portfolio of over 200 finished formulations across various therapeutic categories, including respiratory, oncology, and biologicals. Synapse Pharmatech's official website is www.synapsepharmatech.com.

What Does Synapse Pharmatech Export? — Product Portfolio Analysis

Top Products by Export Value

1Tiotropium$350.0K 2Protein$160.6K

Product Portfolio — Top 2 by Export Value

Synapse Pharmatech exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Tiotropium	Respiratory	$350.0K	7	0.5%	4
2	Protein	Nutritional Supplements	$160.6K	4	1.1%	9

Synapse Pharmatech exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $510.6K. The top category is Respiratory (68.6% of portfolio), followed by Nutritional Supplements (31.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Synapse Pharmatech — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Synapse Pharmatech operates multiple manufacturing facilities across India, each specializing in different product categories:

Unit 1 – North India: This facility is approved by ANVISA Brazil, INVIMA Colombia, PICS, and the European Union. It specializes in oncology, antivirals, general injectables, cephalosporins, hormones, oral solid dosage forms (OSD), ointments, and creams.

Unit 2 – Ahmedabad, Gujarat: Certified by WHO-GMP, this plant focuses on hormones, OSD general and cardiovascular/gastrointestinal products, and offers sachet filling capabilities.

Unit 3 – Gujarat, India: Approved by the European Union, this facility specializes in general injectables, cephalosporins, betalactams, and sterile drops.

Unit 4 – South India: With WHO-GMP approval, this plant is dedicated to biologicals and plasma products.

Unit 5 – North India: Certified by PICS, this facility manufactures tablets, capsules, dry powder inhalers, nasal sprays, and oral liquids.

These facilities are equipped to produce a wide range of pharmaceutical products, ensuring compliance with international quality standards.

3Key Leadership

Synapse Pharmatech is led by a team of experienced professionals:

Pharm. Shalaka Mishra – Managing Director: With over 26 years in the pharmaceutical industry, Shalaka holds a gold medal in Masters in Pharmaceutical Sciences (M.Pharm). Her expertise spans pharma-academics, API industry, and finished formulation industry. She has successfully managed drug development projects for European customers and regulatory filings for USDMFs, as well as generic product development projects and submissions to regulatory authorities like TGA, MHRA, WHO-GDF, and various Latin American agencies.

Pharm. Manish Mishra – Executive Director: With over 28 years in the pharmaceutical industry, including 18 years in international business development, Manish has traveled to more than 45 countries at a senior level. His expertise includes new market developments, partner connections, business development, and agreement finalizations. He has been instrumental in successful partner and Ministry of Health liaisoning, resulting in significant tenders and tech-transfer projects to regulated markets like Canada and the EU.

These leaders drive Synapse Pharmatech's strategic direction and growth in the global pharmaceutical market.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Synapse Pharmatech Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Synapse Pharmatech has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities are approved by various international regulatory bodies, such as the European Union, PICS, ANVISA Brazil, and INVIMA Colombia, indicating compliance with stringent quality standards. However, specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly disclosed in the available sources. The company's focus on obtaining approvals from recognized regulatory agencies underscores its commitment to meeting international standards and expanding its global footprint.

2Emerging Markets

Synapse Pharmatech has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's products are exported to Latin America, CIS, Southeast Asia, and Africa, with over 200 product registrations across five continents. Additionally, Synapse Pharmatech has established distribution partnerships in various countries, including Kenya, Tanzania, Ethiopia, Ghana, Ivory Coast, the Philippines, Nepal, Cambodia, Sri Lanka, Algeria, Turkey, Morocco, Egypt, Sudan, South Sudan, Nigeria, the Democratic Republic of Congo, Uganda, Zimbabwe, Namibia, Botswana, Malaysia, Myanmar, Vietnam, Australia, New Zealand, Papua New Guinea, Fiji, Azerbaijan, Ukraine, Uzbekistan, Russia, Georgia, Peru, Colombia, Mexico, Central America, Uruguay, Chile, Paraguay, Cuba, the Dominican Republic, Guyana, and several MENA and European countries. These partnerships facilitate market entry and distribution, enhancing Synapse Pharmatech's presence in these regions.

Synapse Pharmatech — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Synapse Pharmatech's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly disclosed in the available sources. The company's focus on obtaining approvals from recognized regulatory agencies, such as the European Union, PICS, ANVISA Brazil, and INVIMA Colombia, indicates a commitment to meeting international quality standards. However, without publicly available information on FDA-related activities, a comprehensive assessment of the company's status with the FDA cannot be provided.

2WHO & EU GMP

Synapse Pharmatech's manufacturing facilities are certified by WHO-GMP and EU GMP, reflecting compliance with international quality standards. These certifications are crucial for market access in various regions, including the European Union and other countries that recognize WHO-GMP and EU GMP standards. The company's adherence to these standards underscores its commitment to producing high-quality pharmaceutical products.

3CDSCO & Indian Regulatory

Synapse Pharmatech — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Synapse Pharmatech operates in a competitive landscape with several key players in the pharmaceutical industry. While specific competitors in overlapping categories are not publicly disclosed, the company's focus on niche biopharmaceuticals, including albumin and IVIG injections, as well as oncology products, positions it in specialized market segments. The company's adherence to international quality standards, as evidenced by WHO-GMP and EU GMP certifications, enhances its competitiveness in regulated markets. However, the lack of diversification in its product portfolio, with the top five products accounting for 100% of its export value, may limit its ability to compete across a broader range of therapeutic areas.

2Key Differentiators

Synapse Pharmatech's key differentiators include its specialization in niche biopharmaceuticals, such as albumin and IVIG injections, and its focus on state-of-the-art oncology products and depot injections like leuprolide. The company's adherence to international quality standards, as evidenced by WHO-GMP and EU GMP certifications, underscores its commitment to producing high-quality pharmaceutical products. Additionally, Synapse Pharmatech's extensive network of distribution partnerships across various regions facilitates market access and enhances its global presence.

Strategic Position

Frequently Asked Questions — Synapse Pharmatech

How many pharmaceutical products does Synapse Pharmatech export from India?

Synapse Pharmatech exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Tiotropium ($350.0K), Protein ($160.6K). Total export value is $510.6K.

What is Synapse Pharmatech's total pharmaceutical export value?

Synapse Pharmatech's total pharmaceutical export value is $510.6K, based on 11 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Synapse Pharmatech cover?

Synapse Pharmatech exports across 2 therapeutic categories. The largest are Respiratory (68.6%, 1 products), Nutritional Supplements (31.4%, 1 products).

Get Full Synapse Pharmatech Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.